ArticleDrug safety2023
Provision and Characterization of a Corpus for Pharmaceutical, Biomedical Named Entity Recognition for Pharmacovigilance: Evaluation of Language Registers and Training Data Sufficiency.
Article in Drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectiveMachine learning (ML) systems are widely used for automatic entity recognition in pharmacovigilance. Publicly available datasets do not allow the use of annotated entities independently, focusing on small entity subsets or on single language registers (informal or scientific language). The objective of the current study was to create a dataset that enables independent usage of entities, explores the performance of predictive ML models on different registers, and introduces a method to investigate entity cut-off performance.
methodsA dataset has been created combining different registers with 18 different entities. We applied this dataset to compare the performance of integrated models with models created with single language registers only. We introduced fractional stratified k-fold cross-validation to determine model performance on entity level by using training dataset fractions. We investigated the course of entity performance with fractions of training datasets and evaluated entity peak and cut-off performance.
resultsThe dataset combines 1400 records (scientific language: 790; informal language: 610) with 2622 sentences and 9989 entity occurrences and combines data from external (801 records) and internal sources (599 records). We demonstrated that single language register models underperform compared to integrated models trained with multiple language registers.
conclusionsA manually annotated dataset with a variety of different pharmaceutical and biomedical entities was created and is made available to the research community. Our results show that models that combine different registers provide better maintainability, have higher robustness, and have similar or higher performance. Fractional stratified k-fold cross-validation allows the evaluation of training data sufficiency on the entity level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.